Cotinga Pharmaceuticals Inc. (COTQF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2018 | 2.71 Million USD | 11.65% |
| 2017 | 2.42 Million USD | -3.22% |
| 2016 | 2.5 Million USD | 6.47% |
| 2015 | 2.35 Million USD | 45.91% |
| 2014 | 1.61 Million USD | 71.9% |
| 2013 | 939.72 Thousand USD | 150.04% |
| 2012 | 375.82 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2019 Q2 | 3273.92 USD | 12.59% |
| 2019 Q1 | 2907.95 USD | 6.8% |
| 2019 Q3 | 3636.63 USD | 11.08% |
| 2018 Q3 | 2163.44 USD | 7.93% |
| 2018 Q4 | 2722.75 USD | 25.85% |
| 2018 Q2 | 2004.48 USD | -6.6% |
| 2018 Q1 | 2146.09 USD | -11.5% |
| 2018 FY | 2.71 Million USD | 11.65% |
| 2017 FY | 2.42 Million USD | -3.22% |
| 2017 Q4 | 2425.01 USD | 37.38% |
| 2017 Q3 | 1765.19 USD | 13.51% |
| 2017 Q2 | 1555.11 USD | 4.91% |
| 2017 Q1 | 1482.29 USD | -36.9% |
| 2016 Q4 | 2348.93 USD | 2.58% |
| 2016 Q2 | 2633.79 USD | -17.31% |
| 2016 Q3 | 2289.80 USD | -13.06% |
| 2016 FY | 2.5 Million USD | 6.47% |
| 2016 Q1 | 3185.23 USD | 35.3% |
| 2015 Q3 | 1025.70 USD | -31.85% |
| 2015 FY | 2.35 Million USD | 45.91% |
| 2015 Q2 | 1505.10 USD | 7.74% |
| 2015 Q4 | 2354.22 USD | 129.52% |
| 2015 Q1 | 1396.99 USD | -13.52% |
| 2014 Q3 | 726.97 USD | -8.87% |
| 2014 FY | 1.61 Million USD | 71.9% |
| 2014 Q2 | 797.74 USD | 6.6% |
| 2014 Q4 | 1615.35 USD | 122.2% |
| 2014 Q1 | 748.33 USD | -20.37% |
| 2013 Q4 | 939.73 USD | 210.46% |
| 2013 FY | 939.72 Thousand USD | 150.04% |
| 2013 Q3 | 302.68 USD | -8.7% |
| 2013 Q2 | 331.54 USD | -8.31% |
| 2013 Q1 | 361.57 USD | -3.79% |
| 2012 Q2 | 313.36 USD | 0.0% |
| 2012 Q3 | 385.32 USD | 22.96% |
| 2012 Q4 | 375.82 USD | -2.46% |
| 2012 FY | 375.82 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -9784.595% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 71.354% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 96.258% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -235.27% |
| Rebus Holdings, Inc. | 5.24 Million USD | 48.271% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 95.405% |
| Qrons Inc. | 1.48 Million USD | -82.147% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -121.139% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 96.381% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -5966.854% |
| Skye Bioscience, Inc. | 14.07 Million USD | 80.731% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 94.913% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 71.701% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -543.227% |
| SQZ Biotechnologies Company | 50.03 Million USD | 94.581% |
| Intellipharmaceutics International Inc. | 12 Million USD | 77.419% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 29.594% |
| Mesoblast Limited | 188.44 Million USD | 98.561% |
| Marizyme, Inc. | 26.67 Million USD | 89.835% |
| Genus plc | 485 Million USD | 99.441% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 53.589% |
| Pharming Group N.V. | 244.07 Million USD | 98.889% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -34.899% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -7.762% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 28.641% |
| ContraFect Corporation | 32.53 Million USD | 91.664% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -36.861% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 29.156% |
| IMV Inc. | 37.93 Million USD | 92.851% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 76.977% |
| MultiCell Technologies, Inc. | 1617.67 USD | -167526.339% |
| ONE Bio Corp. | 27.49 Million USD | 90.138% |
| Accustem Sciences Inc. | 1.07 Million USD | -151.255% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 96.497% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -28.206% |
| Q BioMed Inc. | 8.13 Million USD | 66.659% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 96.73% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 47.306% |
| Biomind Labs Inc. | 1.49 Million USD | -80.943% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.716% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 70.011% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 85.266% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -89.115% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1808.33% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1248.297% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 52.807% |
| GB Sciences, Inc. | 5.41 Million USD | 49.947% |
| Alpha Cognition Inc. | 7.16 Million USD | 62.153% |
| HST Global, Inc. | 593.59 Thousand USD | -356.818% |
| CSL Limited | 18.62 Billion USD | 99.985% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -115.348% |
| Halberd Corporation | 728.71 Thousand USD | -272.111% |
| Enzolytics Inc. | 365.26 Million USD | 99.258% |
| Agentix Corp. | 2.51 Million USD | -8.01% |
| Resverlogix Corp. | 67.39 Million USD | 95.977% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -223.302% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.391% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -58.205% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 89.042% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 77.219% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 26.016% |
| AVAX Technologies, Inc. | 3.99 Million USD | 32.103% |
| Zenith Capital Corp. | 27.56 Thousand USD | -9735.834% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.795% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1036.223% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 27.386% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -298.282% |
| Kadimastem Ltd | 3.5 Million USD | 22.632% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3951.519% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 94.605% |
| BioStem Technologies, Inc. | 15.9 Million USD | 82.951% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -483.526% |
| LadRx Corporation | 2.2 Million USD | -23.227% |
| Cell Source, Inc. | 15.8 Million USD | 82.845% |
| Regen BioPharma, Inc. | 5.45 Million USD | 50.315% |
| Regen BioPharma, Inc. | 5.45 Million USD | 50.315% |
| NovAccess Global Inc. | 7.86 Million USD | 65.504% |
| Affymax, Inc. | 8.87 Million USD | 69.433% |
| Itoco Inc. | 1.65 Million USD | -64.029% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -32.174% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 55.172% |
| Mobile Lads Corp. | 1.31 Million USD | -106.444% |
| CytoDyn Inc. | 127.89 Million USD | 97.88% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -6387.335% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -73.115% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 75.45% |
| SYBLEU INC | 681.41 Thousand USD | -297.944% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 55.561% |
| International Stem Cell Corporation | 5.27 Million USD | 48.614% |
| Bioxytran, Inc. | 3.24 Million USD | 16.552% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -333.302% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 41.27% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 93.386% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 87.821% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -33.883% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 50.499% |
| Neutra Corp. | 973.52 Thousand USD | -178.537% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 90.654% |
| PureTech Health plc | 125.58 Million USD | 97.841% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 27.827% |
| IXICO plc | 1.9 Million USD | -42.696% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 86.791% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.376% |
| CSL Limited | 18.62 Billion USD | 99.985% |
| Cellectis S.A. | 249.36 Million USD | 98.913% |